Cholinoceptor blocking drugs: antimuscarinic, ganglionic & neuromuscular blockers

Cholinoceptor blocking drugs (also known as cholinergic antagonists, cholinergic blockers, or anticholinergic agents) are pharmacological compounds that bind selectively to acetylcholine receptors without initiating receptor-mediated intracellular signaling. By occupying the orthosteric binding site or allosteric channels, these agents prevent endogenous acetylcholine (ACh) or exogenously administered cholinomimetic agonists from exerting their physiological actions.

Primary Cholinergic Receptor Subtypes

Cholinergic antagonists fall into three major clinical classes based on the specific receptor populations and anatomical divisions they block: antimuscarinic agents (parasympathoplegics), ganglionic blockers (sympatho- and parasympathoplegics), and neuromuscular junction blockers.

Clinical Significance of the Three Classes

• 1. Muscarinic Antagonists: The most clinically versatile group. By selectively or non-selectively preventing ACh from binding muscarinic receptors at parasympathetic neuroeffector junctions, parasympathetic innervation is interrupted, leaving sympathetic tone unopposed. In addition, they block the exceptional sympathetic cholinergic nerves supplying eccrine sweat glands. Because they do not block nicotinic receptors, they exert negligible effects on skeletal neuromuscular junctions or autonomic ganglia at therapeutic doses.
• 2. Neuromuscular Blocking Agents (NMBDs): Interfere with transmission between somatic motor nerve terminals and nicotinic (N_M) receptors on the skeletal muscle endplate. Used as essential adjuvant relaxants in surgical anesthesia, endotracheal intubation, and orthopedic procedures.
• 3. Ganglionic Blockers: Inhibit nicotinic (N_N) receptors within both sympathetic and parasympathetic ganglia. Because they indiscriminately eliminate all autonomic outflow, their wide-ranging, poorly tolerated side effects render them obsolete for chronic clinical therapy, though they remain important physiological tools.

Natural Alkaloids & Chemical Architecture

Atropine and its naturally occurring congener scopolamine (hyoscine) are tertiary amine alkaloid esters of tropic acid combined with complex organic bases (tropine and scopine, respectively):

• Botanical Sources: Atropine is derived from Atropa belladonna (deadly nightshade) and Datura stramonium (sacred Datura, jimsonweed, or thorn apple). Scopolamine is isolated from Hyoscyamus niger (henbane).
• Stereochemistry: Naturally occurring plant-derived atropine is optically active l-hyoscyamine. During industrial extraction and chemical purification, it readily racemizes into an equimolar racemic mixture of d- and l-hyoscyamine, known pharmacologically as atropine. Nearly all antimuscarinic activity resides in the l-enantiomer.

Pharmacokinetic Principles: Absorption, Distribution & Elimination

• Absorption: Natural tertiary alkaloids and synthetic tertiary amines (atropine, scopolamine, tropicamide, oxybutynin) are lipophilic and rapidly absorbed across the gastrointestinal mucosa, conjunctival membranes, and intact skin. Scopolamine is effectively delivered via transdermal patches. Conversely, quaternary amines (ipratropium, tiotropium, glycopyrrolate, propantheline) carry a permanent positive charge, limiting oral bioavailability to only 10% to 30% due to poor lipid membrane partition.
• Distribution: Tertiary agents distribute extensively throughout whole-body tissues. Significant concentrations cross the blood-brain barrier within 30 to 60 minutes. Scopolamine achieves rapid, complete CNS equilibrium, yielding greater central sedative and amnestic actions than atropine. Quaternary amine derivatives are largely excluded from the CNS at therapeutic doses, restricting their pharmacological profile to peripheral tissues.
• Metabolism & Excretion: Elimination of atropine from plasma is biphasic:
  • Rapid distribution phase half-life: t_1/2 ≈ 2 hours.
  • Slow elimination phase half-life: t_1/2 ≈ 13 hours.
  Approximately 50% of an administered atropine dose is excreted unchanged in the urine; the remainder is cleared via hepatic enzymatic hydrolysis and glucuronide conjugation.
• Organ-Specific Dissociation Kinetics: While systemic antimuscarinic effects decline rapidly across visceral tissues, ocular blockade persists markedly longer: effects on the iris and ciliary muscle persist for ≥ 72 hours and up to 7 to 10 days due to drug trapping in pigmented ocular structures.

Mechanism of Competitive & Inverse Agonism

Atropine causes reversible, competitive (surmountable) blockade of muscarinic cholinoceptors. The parallel rightward shift in the agonist log concentration-response curve can be completely surmounted by increasing concentrations of ACh or cholinomimetic agonists.

• Molecular Signaling Interruption: Atropine prevents agonist-induced G-protein activation, halting G_q-mediated stimulation of phospholipase C (blocking IP₃/DAG production) and preventing G_i-mediated inhibition of adenylyl cyclase.
• The Inverse Agonist Concept: While classical pharmacology considered antimuscarinics to be neutral competitive antagonists, molecular cloning shows that muscarinic receptors display baseline constitutive activity (spontaneous G-protein coupling in the absence of agonist). Most clinical antimuscarinics—including atropine, pirenzepine, trihexyphenidyl, ipratropium, and glycopyrrolate—are actually inverse agonists that bind and stabilize the inactive (R) receptor conformation, suppressing constitutive basal signaling.

Differential Tissue Sensitivity to Antimuscarinic Blockade

Target organs display markedly different sensitivity thresholds to muscarinic blockade. Doses must be titrated carefully to achieve therapeutic effects without precipitating broad anticholinergic toxicity:

1. Highest Sensitivity: Salivary, bronchial, and eccrine sweat glands (dry mouth, reduced bronchial secretions, and anhidrosis occur at lowest doses).
2. Intermediate Sensitivity: Ocular pupillary constrictor and ciliary muscles, followed by the cardiac sinoatrial node (mydriasis, cycloplegia, and tachycardia require moderate doses).
3. Lowest Sensitivity: Gastrointestinal tract smooth muscle tone and gastric parietal cell acid secretion (inhibiting hydrochloric acid requires very high doses that cause severe dry mouth and urinary retention).

Note on Table Values: Dissociation constants (K_d) are expressed relative to atropine (defined as 1). Smaller numerical values indicate higher binding affinity. AF-DX 116 and 4-DAMP are experimental research antagonists.

1. Central Nervous System (CNS)

• Dose-Dependent Actions of Atropine: In therapeutic doses (0.5 to 1.0 mg), atropine produces minimal central stimulation, exerting mild, slow sedative effects on subcortical centers. At toxic doses, central excitation dominates, manifesting as restlessness, irritability, disorientation, visual hallucinations, and delirium, ultimately progressing to coma and medullary respiratory depression.
• Scopolamine: Penetrates the blood-brain barrier rapidly, producing significant central depression at therapeutic doses. Manifests as drowsiness, fatigue, euphoria, and amnesia. Highly effective in mitigating vestibular motion sickness by suppressing cholinergic transmission in the vestibular nuclei and the chemoreceptor trigger zone.
• Parkinsonism & Extrapyramidal Motor Control: The normal basal ganglia circuit maintains an enzymatic balance between inhibitory dopamine (from the substantia nigra) and excitatory acetylcholine (from striatal interneurons). In Parkinson’s disease, loss of dopaminergic neurons creates a relative cholinergic excess. Centrally active antimuscarinics (benztropine, trihexyphenidyl) suppress this cholinergic overactivity, reducing tremor and rigidity.

2. The Eye

• Mydriasis: Antimuscarinics competitively block M₃ receptors on the pupillary constrictor (sphincter pupillae) muscle of the iris. Unopposed sympathetic tone via α₁ receptors on the radial pupillary dilator muscle causes pupil dilation (mydriasis) and complete unresponsiveness to light.
• Cycloplegia: Blockade of M₃ receptors on the ciliary muscle prevents parasympathetically driven contraction. The ciliary body relaxes, pulling the zonular fibers taut, which flattens the crystalline lens. This eliminates the eye’s ability to accommodate for near vision (cycloplegia). The atropinized eye is fixed for far vision.
• Intraocular Pressure (IOP) Hazard: In patients with narrow-angle glaucoma, pupillary dilation causes the iris root to fold backward into the iridocorneal angle, physically occluding the trabecular meshwork. This halts aqueous humor drainage into the canal of Schlemm, precipitating acute angle-closure glaucoma (an ophthalmologic emergency).
• Lacrimal Secretions: M₃ blockade decreases tear secretion, producing complaints of dry or “sandy” eyes.

3. Cardiovascular System

• Biphasic Heart Rate Response:
  • Low Therapeutic Doses (<0.5 mg Atropine): Frequently causes a transient, paradoxical bradycardia. This is mediated by selective blockade of presynaptic autoinhibitory M₁ receptors on vagal postganglionic terminals, which normally provide negative feedback to shut down ACh release. Blocking these autoreceptors increases ACh exocytosis into the sinoatrial node.
  • Moderate to High Doses (≥1.0 mg Atropine): Produces progressive, marked tachycardia by competitively blocking postjunctional M₂ receptors on cardiac nodal pacemaker cells, abolishing vagal inhibitory tone.
• Atrioventricular (AV) Conduction: Facilitates AV nodal transmission, shortening the PR interval on the electrocardiogram. Muscarinic blockade protects against vagally mediated AV block. Ventricular myocardium is largely spared due to sparse direct parasympathetic innervation.
• Vascular System & Hemodynamics: Most vascular beds lack direct parasympathetic innervation. However, nearly all vascular endothelial cells express uninnervated M₃ receptors that synthesize nitric oxide (NO) when exposed to circulating muscarinic agonists. Atropine completely blocks agonist-mediated vasodilation.
• Atropine Flush: At toxic or near-toxic doses, antimuscarinics cause cutaneous vasodilation, particularly across the blush areas of the face and upper chest. This reflects a non-cholinergic compensatory reflex to dissipate heat caused by sweat gland paralysis.

4. Respiratory System

Both airway smooth muscle and submucosal seromucous glands receive vagal innervation containing M₃ receptors. Antimuscarinic drugs cause:

• Bronchodilation: Relaxes bronchial smooth muscle, reducing airway resistance. While less effective than β₂-adrenoceptor agonists (e.g., salbutamol) in acute asthma, antimuscarinics are exceptionally valuable in chronic obstructive pulmonary disease (COPD), where vagal tone is the primary reversible element of airway obstruction.
• Antisecretory Action: Dries secretions across the pharynx, larynx, trachea, and bronchi, reducing the risk of postoperative atelectasis and laryngospasm.
• Autoinhibitory M₂ Consideration: Non-selective antimuscarinics block autoinhibitory M₂ receptors on airway postganglionic parasympathetic nerves, increasing ACh release that can counteract M₃ bronchodilation. Inhaled quaternary agents like tiotropium dissociate rapidly from M₂ but slowly from M₃, maintaining sustained bronchodilation.

5. Gastrointestinal Tract

• Motility & Tone: Causes dramatic relaxation of visceral smooth muscle from the stomach to the colon. Decreases muscle tone, amplitude, and frequency of peristaltic contractions, significantly prolonging gastric emptying and intestinal transit time. Intestinal paralysis is generally temporary; local enteric nervous system (ENS) pacemaking typically re-establishes basal peristalsis within 1 to 3 days.
• Secretions: Salivary glands are exquisitely sensitive; M₃ blockade leads to profound xerostomia (dry mouth). Gastric acid secretion by parietal cells is relatively resistant to atropine because acid output is driven by overlapping histaminergic and gastrinergic pathways; high doses decrease acid, pepsin, and mucin volume, but cause intolerable dry mouth and cycloplegia. M₁-selective antagonists (pirenzepine, telenzepine) suppress basal and stimulated acid production more selectively. Pancreatic and biliary secretions are largely unaffected, as they are primarily governed by hormonal signals (secretin, cholecystokinin).

6. Genitourinary Tract & Sweat Glands

• Urinary Bladder: Inhibits M₂ and M₃ receptors, relaxing the detrusor smooth muscle while contracting the internal urethral sphincter. Increases functional bladder capacity, decreases voiding frequency, and suppresses involuntary detrusor contractions. Can precipitate acute urinary retention in elderly men with benign prostatic hyperplasia (BPH). Ureters are relaxed; uterine smooth muscle is largely unaffected.
• Thermoregulatory Sweating: Thermoregulatory eccrine sweat glands are innervated by specialized sympathetic postganglionic cholinergic fibers acting via M₃ receptors. Atropine suppresses sweating, producing dry skin. In adults, large doses elevate core temperature; in infants and young children, even therapeutic doses can trigger dangerous hyperthermia (“atropine fever”).

The Anticholinergic Toxidrome

Acute toxicity from atropine, deadly nightshade berries, or drugs with secondary anticholinergic properties (TCAs, first-generation antihistamines, phenothiazines) produces a characteristic constellation of clinical signs:

Vulnerable Populations & Antidotal Management

• Pediatric Lethality: Infants and young children are exceptionally sensitive to the hyperthermic effects of atropine. While adults have survived overdoses exceeding 400 mg with intensive care, pediatric fatalities have occurred with doses as low as 2 mg.
• Symptomatic & Supportive Therapy: Core cooling blankets to manage hyperthermia, fluid resuscitation, catheterization for urinary retention, and intravenous benzodiazepines (diazepam) for central seizures and psychomotor agitation.
• Specific Antidote (Physostigmine): Reserved for severe, life-threatening anticholinergic delirium or intractable supraventricular arrhythmias. As a tertiary amine, physostigmine penetrates the blood-brain barrier and inhibits acetylcholinesterase, raising endogenous ACh levels to compete out atropine centrally and peripherally. Quaternary AChE inhibitors (neostigmine, edrophonium) do not cross the blood-brain barrier and treat only peripheral manifestations.

Management of Cholinesterase Inhibitor Poisoning

Agricultural organophosphate insecticides (parathion, malathion) and military nerve gases (sarin, soman, VX) irreversibly phosphorylate acetylcholinesterase, causing overwhelming cholinergic crisis across muscarinic, nicotinic, and central synapses.

• 1. High-Dose Antimuscarinic Therapy: Tertiary amine atropine is administered immediately (1 to 2 mg IV every 5 to 15 minutes) until full “atropinization” is achieved (clearing of pulmonary secretions, resolution of bronchoconstriction, and reversal of miosis). Severe poisonings may require up to 1 gram of atropine per day for several weeks. Critical Caveat: Atropine reverses muscarinic and central effects, but has zero effect on nicotinic neuromuscular paralysis!
• 2. Cholinesterase Regenerator Compounds (Oximes):
  • Pralidoxime (2-PAM): A nucleophilic oxime that attacks the phosphorus atom of the organophosphate-enzyme complex, dislodging the inhibitor and restoring active acetylcholinesterase. Effective primarily if given before the phosphorylated enzyme undergoes “aging” (chemical loss of an alkyl side chain, making inhibition permanent). Administered as an IV infusion of 1 to 2 g over 15 to 30 minutes. Because of its charged quaternary ammonium structure, pralidoxime does not cross the blood-brain barrier and works primarily at skeletal neuromuscular junctions.
  • Diacetylmonoxime (DAM): A tertiary oxime that crosses the blood-brain barrier to regenerate central cholinesterase.
  • Carbamate Caveat: Pralidoxime is not indicated in reversible carbamate poisoning (e.g., neostigmine, physostigmine), as carbamylated enzyme spontaneously reactivates and oximes may add secondary toxicity.
• 3. Prophylactic Pretreatment: In anticipation of nerve gas exposure (chemical warfare), troops are pretreated with the reversible carbamate inhibitor pyridostigmine. Pyridostigmine reversibly occupies a fraction of the enzyme pool, shielding it from irreversible phosphorylation by organophosphates. When the nerve agent clears, pyridostigmine dissociates, leaving functional enzyme available. Simultaneous atropine is co-administered to control muscarinic excess.

Management of Mushroom Poisoning

Contraindications to Antimuscarinics

• Glaucoma: Absolutely contraindicated in patients with closed-angle glaucoma or narrow anterior chamber angles.
• Benign Prostatic Hyperplasia (BPH): Contraindicated in elderly men with bladder outlet obstruction or prostatic hypertrophy due to the risk of precipitating acute, painful urinary retention.
• Gastric Ulcer & Intestinal Atony: By delaying gastric emptying, antimuscarinics increase gastric distention and exacerbate ulcer symptoms; also contraindicated in paralytic ileus, toxic megacolon, and pyloric stenosis.

Ganglion-blocking agents competitively inhibit cholinergic neurotransmission mediated by nicotinic N_N (N₂) receptors across all postganglionic autonomic neurons (both sympathetic and parasympathetic).

Mechanisms & Pharmacological Profiles

• Non-Depolarizing Competitive Blockade: Synthetic amines that compete with ACh for N_N receptors:
  • Hexamethonium & Tetraethylammonium (TEA): Quaternary ammonium compounds. Hexamethonium blocks transmission primarily by physically occluding the open ion channel pore rather than competing for the ACh binding site. Poorly and erratically absorbed from the gut.
  • Trimethaphan: A short-acting sulfonium competitive blocker that directly occupies the nicotinic receptor site (surmountable). Orally inactive; administered via continuous intravenous infusion.
  • Mecamylamine: A synthetic secondary amine developed to achieve complete, reliable gastrointestinal absorption. Readily crosses the blood-brain barrier, causing central sedation, tremor, choreiform movements, and mental aberrations.

Organ System Effects Based on Dominant Autonomic Tone

Because ganglion blockers shut off all autonomic outflow indiscriminately, the clinical effect on an organ depends on which division of the autonomic nervous system exerts the predominant resting baseline tone:

Clinical Applications & Nicotine Toxicology

• Clinical Uses: Largely obsolete. Trimethaphan was used historically for controlled hypotension in neurosurgery (to minimize operative field bleeding), dissecting aortic aneurysms, and electroconvulsive therapy. Mecamylamine has been investigated as an oral smoking cessation adjunct with transdermal nicotine patches to block central reward pathways.
• Nicotine: An alkaloid that acts as both a ganglion stimulant and a ganglion blocker. At low doses, it depolarizes autonomic ganglia, causing simultaneous discharge of sympathetic nerves (hypertension, tachycardia via adrenal medullary catecholamines) and parasympathetic nerves (increased salivation, intestinal hypermotility). At high toxic doses, initial stimulation gives way to persistent depolarizing blockade, precipitating vascular collapse, gastrointestinal arrest, and neuromuscular respiratory paralysis.

Neuromuscular blocking drugs (NMBDs) block cholinergic transmission between somatic motor nerve terminals and nicotinic N_M receptors on the skeletal muscle motor endplate, producing complete skeletal muscle relaxation.

Non-Depolarizing (Competitive) Agents

The botanical prototype is d-tubocurarine. Modern synthetic and semi-synthetic analogs are subclassified by duration of action:

• Short-Acting: Mivacurium (metabolized by plasma cholinesterase; duration ~15–20 minutes).
• Intermediate-Acting: Atracurium, Cisatracurium, Vecuronium, Rocuronium (duration ~30–60 minutes).
• Long-Acting: Pancuronium, Doxacurium, Pipecuronium (duration >60–120 minutes).

Mechanism of Action: Low Dose vs. High Dose

• Low Therapeutic Doses: Act as classical competitive antagonists. They compete directly with ACh for the two α-subunits of the nicotinic N_M receptor without stimulating the channel, preventing motor endplate depolarization and subsequent muscle action potentials. This competitive blockade is readily reversed by acetylcholinesterase inhibitors (e.g., neostigmine, edrophonium), which elevate endogenous synaptic ACh levels.
• High Doses: Non-depolarizing molecules enter and physically occlude the central ion channel pore. This non-competitive channel block severely weakens transmission and cannot be reversed by acetylcholinesterase inhibitors.

Pharmacokinetics & Clearance Pathways

• Polar Structure: All NMBDs possess two or more bulky, positively charged quaternary ammonium groups, preventing oral absorption and excluding them from the central nervous system and placental transfer. Must be administered intravenously.
• Elimination Pathways:
  • Atracurium & Cisatracurium: Undergo spontaneous non-enzymatic chemical breakdown at physiological pH and temperature (Hofmann elimination) alongside plasma ester hydrolysis. Because clearance is independent of renal or hepatic function, they are the agents of choice in patients with renal failure or hepatic disease. (Atracurium breakdown yields laudanosine, which can trigger seizures at high concentrations; cisatracurium produces significantly less laudanosine).
  • Vecuronium & Rocuronium: Undergo biliary and hepatic elimination; duration is prolonged in hepatic failure.
  • Pancuronium: Excreted unchanged in urine; duration is significantly prolonged in renal impairment.

Drug Interactions with Non-Depolarizing Blockers

• Cholinesterase Inhibitors: Neostigmine, pyridostigmine, and edrophonium reverse competitive blockade. However, excessive doses can produce a depolarizing block by generating toxic ACh concentrations at the endplate.
• Inhalation Anesthetics: Volatile halogenated hydrocarbons (halothane, isoflurane, sevoflurane) enhance and prolong neuromuscular blockade via central nervous system depression, enhanced local blood flow, and stabilizing actions at the motor endplate.
• Aminoglycoside Antibiotics: Streptomycin, gentamicin, and tobramycin inhibit presynaptic voltage-gated Ca²⁺ channels, preventing ACh release. They act synergistically with competitive blockers to deepen neuromuscular paralysis.
• Calcium Channel Blockers: Enhance competitive neuromuscular blockade by reducing trans-sarcolemmal calcium influx.

The clinical prototype and only available depolarizing neuromuscular blocker is succinylcholine (suxamethonium), a flexible molecule composed of two conjugated acetylcholine molecules.

Biphasic Mechanism of Action

• Phase I Block (Depolarizing Phase): Succinylcholine binds to the nicotinic N_M receptor, opening the associated ion channel and depolarizing the motor endplate. Unlike acetylcholine (which is hydrolyzed in microseconds by synaptic acetylcholinesterase), succinylcholine is not metabolized by acetylcholinesterase, persisting in the cleft and producing sustained depolarization. Because voltage-gated sodium channels in the perijunctional sarcolemma require repolarization to reset, they remain trapped in the inactivated state. This manifests as initial, transient muscle fasciculations followed rapidly by complete flaccid paralysis. Phase I blockade is augmented, not reversed, by cholinesterase inhibitors!
• Phase II Block (Desensitization Phase): With continued, prolonged exposure or high cumulative doses, the endplate membrane gradually repolarizes, but the nicotinic receptor becomes desensitized and refractory to acetylcholine. The junction behaves electrophysiologically like a non-depolarizing competitive block, displaying tetanic fade and partial reversibility with acetylcholinesterase inhibitors.

Pharmacokinetics: Ultra-Short Action & Metabolism

• Onset & Duration: Injected intravenously. Produces rapid muscular relaxation within 30 to 60 seconds, with a brief duration of action (5 to 10 minutes) due to rapid redistribution and hydrolysis by circulating plasma cholinesterase (also termed pseudocholinesterase or butyrylcholinesterase) in the liver and blood.
• Clinical Indication: The drug of choice for rapid sequence intubation (RSI) during emergency airway management, full-stomach aspiration risk, and electroconvulsive shock therapy (ECT).

Adverse Effects & Clinical Complications

• 1. Prolonged Apnea: Patients with an inherited deficiency or atypical variant of plasma cholinesterase (quantified by the dibucaine number) cannot hydrolyze succinylcholine, leading to prolonged diaphragmatic paralysis and apnea lasting hours. Requires continued mechanical ventilation.
• 2. Malignant Hyperthermia: When administered alongside volatile halogenated anesthetics (especially halothane), succinylcholine can trigger malignant hyperthermia in patients carrying genetic mutations in the skeletal muscle sarcoplasmic reticulum ryanodine receptor (RyR1) or the dihydropyridine receptor. Uncontrolled calcium efflux triggers muscle rigidity, hypermetabolism, hypercapnia, and dangerous fever. Treatment: Discontinue offending agents, provide active cooling, and administer intravenous dantrolene immediately.
• 3. Hyperkalemia: Sustained endplate depolarization releases intracellular potassium into circulation. In patients with extensive burns, massive crush trauma, spinal cord transection, or denervating neuromuscular disease, upregulation of extrajunctional nicotinic receptors can trigger life-threatening hyperkalemia, cardiac arrhythmias, and cardiac arrest.
• 4. Postoperative Myalgia: Vigorous, unsynchronized fasciculations prior to Phase I paralysis cause postoperative muscle pain, particularly across the neck, back, and abdomen.
• 5. Increased Pressures: Fasciculations cause transient elevations in intraocular pressure (risking globe rupture in open-eye trauma) and intragastric pressure (increasing regurgitation risk).

In contrast to neuromuscular junction blockers used in anesthesia, spasmolytic muscle relaxants reduce spasticity resulting from upper motor neuron lesions (cerebral palsy, stroke, spinal cord transection, multiple sclerosis) characterized by heightened excitability of α- and γ-motor systems.

The following authoritative medical pharmacology texts and guidelines support this curriculum study note:

• Katzung’s Basic & Clinical Pharmacology: Katzung, B.G. and Vanderah, T.W. (2021) Basic & Clinical Pharmacology. 15th edn. New York: McGraw-Hill Education. [Chapter 8: Cholinoceptor-Blocking Drugs; Chapter 27: Skeletal Muscle Relaxants].
• Goodman & Gilman’s Pharmacological Basis of Therapeutics: Brunton, L.L., Hilal-Dandan, R. and Knollmann, B.C. (2018) Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 13th edn. New York: McGraw-Hill Education. [Chapter 9: Muscarinic Receptor Agonists and Antagonists; Chapter 11: Nicotine and Agents Acting at the Neuromuscular Junction and Autonomic Ganglia].
• Lippincott Illustrated Reviews: Pharmacology: Whalen, K. (2019) Lippincott Illustrated Reviews: Pharmacology. 7th edn. Philadelphia: Wolters Kluwer. [Chapter 5: Cholinergic Antagonists].
• Rang & Dale’s Pharmacology: Ritter, J.M., Flower, R., Henderson, G., Loke, Y.K., MacEwan, D. and Rang, H.P. (2020) Rang & Dale’s Pharmacology. 9th edn. Edinburgh: Elsevier. [Chapter 14: Cholinergic Transmission].
• Uganda Clinical Guidelines: Ministry of Health Uganda (2023) Uganda Clinical Guidelines: National Guidelines for the Management of Common Conditions. Kampala: Ministry of Health. [Section 1.8: Management of Acute Poisoning and Chemical Exposures – Organophosphate Toxicity].